Targeted transdermal scopolamine delivery over the salivary glands for sialorrhea: Dose–response and systemic safety in rats

Puntos clave

• Transdermal scopolamine effectively reduces sialorrhea in rats, highlighting a potential treatment option.
• In doses ranging from low to high, scopolamine significantly alleviates drooling without major systemic safety concerns.
• Assessment using a rat model allows for controlled testing of scopolamine on salivary gland activity.
• Results suggest promising implications for future therapies targeting sialorrhea in clinical settings.